|
Liver Cirrhosis
|
0.200 |
Biomarker
|
disease |
BEFREE |
Personalized strategies employing the genetic risk conferred by ATG16L1 and PNPLA3 may be used for risk-based surveillance in cirrhosis.
|
31484215 |
2019 |
|
Liver Cirrhosis
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Carriage of HSD17B13 rs72613567:TA attenuated the risk for developing cirrhosis associated with PNPLA3 rs738409:G in both men and women but the protective effect against the subsequent development of HCC was only observed in men (p=1.72×10-4; ORallelic, 0.75; 95% CI, 0.64-0.87).
|
31630428 |
2019 |
|
Liver Cirrhosis
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Second, although the strongest genetic risk alleles for NAFLD (ie, the 148Met allele in PNPLA3 and the 167Lys allele in TM6SF2) are associated with increased liver fat content and progression to NASH and cirrhosis, these alleles are also unexpectedly associated with an apparent protection from cardiovascular disease.
|
30174213 |
2019 |
|
Liver Cirrhosis
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
PNPLA3 rs738409 G allele carriers with genotype 1b HCV cirrhosis have lower viral load but develop liver failure at younger age.
|
31527889 |
2019 |
|
Liver Cirrhosis
|
0.200 |
Biomarker
|
disease |
BEFREE |
These genetic variations also did not mediate the effect of <i>PNPLA3 rs738409</i> SNP for liver developing liver fibrosis or liver cirrhosis.
|
30875804 |
2019 |
|
Liver Cirrhosis
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Genetic variants in PNPLA3 and TM6SF2 predispose to the development of hepatocellular carcinoma in individuals with alcohol-related cirrhosis.
|
29535416 |
2018 |
|
Liver Cirrhosis
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
No significant differences in the genotype distribution of PNPLA3 (P = 0.90) or TM6SF2 (P = 0.72) were observed between patients with cirrhosis and patients without cirrhosis.
|
30161167 |
2018 |
|
Liver Cirrhosis
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Correction: Genetic Variants in PNPLA3 and TM6SF2 Predispose to the Development of Hepatocellular Carcinoma in Individuals With Alcohol-Related Cirrhosis.
|
29895985 |
2018 |
|
Liver Cirrhosis
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
This meta-analysis pooled four studies with 1135 cases of chronic hepatitis B (CHB) to evaluate the impact of PNPLA3 SNP on liver steatosis and also pooled five studies with 3713 cases of CHB to evaluate the impact of PNPLA3 SNP on cirrhosis.
|
29218813 |
2018 |
|
Liver Cirrhosis
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
PNPLA3 I148M was associated with a stepwise increase in liver fat content of up to 28% in MM vs. II-homozygotes (P-trend = 0.0001) and with ORs of 2.03 (1.52-2.70) for NAFLD (P = 3×10-7), 3.28 (2.37-4.54) for cirrhosis (P = 4×10-12), and 0.95 (0.86-1.04) for IHD (P = 0.46).
|
29228164 |
2018 |
|
Liver Cirrhosis
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Prdevious meta-analyses assess whether or not patatin-like phospholipase domain containing 3 (PNPLA3) (rs738409 C > G) was associated with increased risk of hepatocellular carcinoma (HCC) in Caucasians patients with hepatitis C virus (HCV)-related cirrhosis, these meta-analyses did not provide firm conclusions.
|
29089161 |
2018 |
|
Liver Cirrhosis
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Carriage of rs738409:G in PNPLA3 is associated with an increased risk of developing alcohol-related cirrhosis and has a significant negative effect on survival.
|
28161471 |
2017 |
|
Liver Cirrhosis
|
0.200 |
Biomarker
|
disease |
BEFREE |
Among them, 86 patients who were followed up for >5 years and without liver cirrhosis were analyzed to clarify the relationship between PNPLA3 genotype and long-term changes in biomarkers.
|
27862719 |
2017 |
|
Liver Cirrhosis
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Among 270 HBV-infected patients, concurrent fatty liver was found in 107 patients (39.6%) and was associated with metabolic risks, cirrhosis (P = 0.016) and PNPLA3 rs738409 CG/GG genotype (P = 0.002).
|
27547913 |
2017 |
|
Liver Cirrhosis
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
PNPLA3 genotypes were also associated with higher risk of developing liver fibrosis and cirrhosis in dominant (aOR: 1.98, P=2.20*10-5; aOR: 1.67, P=0.008, respectively) and recessive (aOR: 3.94, P=5.16*10-5; aOR: 3.02, P=0.003, respectively) models.
|
28338112 |
2017 |
|
Liver Cirrhosis
|
0.200 |
Biomarker
|
disease |
BEFREE |
The familiality and hereditability of alcohol-related cirrhosis is not as well-documented but three strong candidate genes PNPLA3, TM6SF2 and MBOAT7, have been identified.
|
27575312 |
2017 |
|
Liver Cirrhosis
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
TM6SF2 C/T or T/T in conjunction with PNPLA3 G/G variants may be potential genetic risk factors for developing HCC in alcohol-related cirrhosis.
|
26493626 |
2016 |
|
Liver Cirrhosis
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
The PNPLA3 CG/GG SNP at rs738409 was significantly associated with the presence of cirrhosis (odds ratio [OR], 1.76; 95% confidence interval [CI], 1.34-2.30), after adjusting for age, sex, diabetes, and race.
|
26305067 |
2016 |
|
Liver Cirrhosis
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
The PNPLA3 Genetic Variant rs738409 Influences the Progression to Cirrhosis in HIV/Hepatitis C Virus Coinfected Patients.
|
27973562 |
2016 |
|
Liver Cirrhosis
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Frequency of the PNPLA3 minor (G) allele was increased in patients with NASH-cirrhosis compared with non-cirrhotic NAFLD and controls (allele frequency: 0.598 versus 0.367 versus 0.2, respectively, p < 0.001), and different between the latter two groups (p < 0.001).
|
27150500 |
2016 |
|
Liver Cirrhosis
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
We identified variants in the MBOAT7 (P = 1.03 × 10(-9)) and TM6SF2 (P = 7.89 × 10(-10)) genes as new risk loci and confirmed rs738409 in PNPLA3 as an important risk locus for alcohol-related cirrhosis (P = 1.54 × 10(-48)) at a genome-wide level of significance.
|
26482880 |
2015 |
|
Liver Cirrhosis
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Our findings suggest that patients at risk for liver cirrhosis may benefit from PNPLA3 genotyping and thus more intensive monitoring if the rs738409 C>G polymorphism is identified.
|
25378656 |
2015 |
|
Liver Cirrhosis
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Single nucleotide polymorphisms (SNPs) in the epidermal growth factor (EGF, rs4444903), patatin-like phospholipase domain-containing protein 3 (PNPLA3, rs738409) genes, and near the interleukin-28B (IL28B, rs12979860) gene are linked to treatment response, fibrosis, and hepatocellular carcinoma (HCC) in chronic hepatitis C. Whether these SNPs independently or in combination predict clinical deterioration in hepatitis C virus (HCV)-related cirrhosis is unknown.
|
25504078 |
2014 |
|
Liver Cirrhosis
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, using two histologically characterized cohorts encompassing steatosis, steatohepatitis, fibrosis and cirrhosis (combined n=1,074), we demonstrate a new association, independent of potential confounding factors (age, BMI, type 2 diabetes mellitus and PNPLA3 rs738409 genotype), with advanced hepatic fibrosis/cirrhosis.
|
24978903 |
2014 |
|
Liver Cirrhosis
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Moreover, PNPLA3 148M allele carriers showed an increased incidence of cirrhosis (P-value < 0.001).
|
24102786 |
2014 |